लोड हो रहा है...

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways

INTRODUCTION: Osteoporosis is an osteolytic bone condition characterized by decreased bone strength and increased bone fragility. It is the result of elevated formation or activity of bone-resorbing osteoclasts. Although current therapeutic agents are efficacious against osteoclast-mediated bone los...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Drug Des Devel Ther
मुख्य लेखकों: Li, Xuedong, Lin, Xixi, Wu, Zuoxing, Su, Yuangang, Liang, Jiamin, Chen, Runfeng, Yang, Xue, Hou, Lei, Zhao, Jinmin, Liu, Qian, Xu, Feng
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Dove 2021
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7800467/
https://ncbi.nlm.nih.gov/pubmed/33442237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S283694
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!